

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1617srh

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 5 MAY 10 CA/Capplus enhanced with 1900-1906 U.S. patent records
NEWS 6 MAY 11 KOREAPAT updates resume
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/Capplus and
USPATFULL/USPAT2
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/Capplus
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 13 JUL 11 CHEMSAFE reloaded and enhanced
NEWS 14 JUL 14 FSTA enhanced with Japanese patents
NEWS 15 JUL 19 Coverage of Research Disclosure reinstated in DWPI

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:11:36 ON 21 JUL 2006

=>

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 09:11:51 ON 21 JUL 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 JUL 2006 HIGHEST RN 894691-89-5
DICTIONARY FILE UPDATES: 19 JUL 2006 HIGHEST RN 894691-89-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:


<http://www.cas.org/ONLINE/UG/regprops.html>

=> s norcisapride
L1 3 NORCISAPRIDE

=> d tot

L1 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN
RN 202590-69-0 REGISTRY
ED Entered STN: 12 Mar 1998
CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[(3S,4R)-3-methoxy-4-piperidinyl]-
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzamide, 4-amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidinyl)-,
cis-(+)-
OTHER NAMES:
CN (+)-Norcisapride
CN Ticalopride
FS STEREOSEARCH
MF C14 H20 Cl N3 O3
CI COM
SR CA
LC STN Files: ANABSTR, BIOSIS, CA, CAPLUS, IMSRESEARCH, TOXCENTER, USAN,
USPAT2, USPATFULL

Absolute stereochemistry. Rotation (+).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

15 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
15 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN
RN 186260-03-7 REGISTRY
ED Entered STN: 19 Feb 1997
CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[(3R,4S)-3-methoxy-4-piperidinyl]-
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzamide, 4-amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidinyl)-,
cis-(-)-
OTHER NAMES:
CN (-)-Norcisapride
FS STEREOSEARCH
MF C14 H20 Cl N3 O3
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (-).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
9 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN
RN 83863-69-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[(3R,4S)-3-methoxy-4-piperidinyl]-
, rel- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzamide, 4-amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidinyl)-, cis-
OTHER NAMES:
CN (±)-Norcisapride
CN Norcisapride
FS STEREOSEARCH
DR 86718-38-9
MF C14 H20 Cl N3 O3
SR European Union (EU)
LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN,
IMSRESEARCH, PHAR, TOXCENTER, USPAT2, USPATFULL
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

39 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 39 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> sel rn 3
 E1 THROUGH E1 ASSIGNED

=> fil hcapl medl biosis uspatf wpids
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
10.98	11.19

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 09:12:36 ON 21 JUL 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 09:12:36 ON 21 JUL 2006

FILE 'BIOSIS' ENTERED AT 09:12:36 ON 21 JUL 2006
 Copyright (c) 2006 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 09:12:36 ON 21 JUL 2006
 CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 09:12:36 ON 21 JUL 2006
 COPYRIGHT (C) 2006 THE THOMSON CORPORATION

=> s el
 L2 52 83863-69-8/BI


=> dup rem l2
 PROCESSING COMPLETED FOR L2
 L3 45 DUP REM L2 (7 DUPLICATES REMOVED)

=> d ibib abs 40-45

L3 ANSWER 40 OF 45 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1988:406425 HCAPLUS
 DOCUMENT NUMBER: 109:6425
 TITLE: Preparation of 4-(aroylamino)-1-piperidinebutanamides
 as antidiarrheal agents
 INVENTOR(S): Van Daele, Georges Henri Paul; Vlaeminck, Freddy
 Francois; De Cleyn, Michael Anna Jozef; De, Cleyn
 Michael Anna Jozef
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
 SOURCE: Eur. Pat. Appl., 29 pp.

CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 251417	A2	19880107	EP 1987-201255	19870701
EP 251417	A3	19890426		
EP 251417	B1	19930414		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 1311755	A1	19921222	CA 1987-539401	19870611
SU 1620049	A3	19910107	SU 1987-4202790	19870629
DK 8703363	A	19880104	DK 1987-3363	19870630
JP 63022575	A2	19880130	JP 1987-162509	19870701
JP 2512755	B2	19960703		
IL 83045	A1	19910718	IL 1987-83045	19870701
AT 88181	E	19930415	AT 1987-201255	19870701
ES 2054653	T3	19940816	ES 1987-201255	19870701
FI 8702930	A	19880104	FI 1987-2930	19870702
FI 90863	B	19931231		
NO 8702781	A	19880104	NO 1987-2781	19870702
NO 171908	B	19930208		
NO 171908	C	19930519		
AU 8775067	A1	19880107	AU 1987-75067	19870702
AU 593660	B2	19900215		
ZA 8704810	A	19890222	ZA 1987-4810	19870702
HU 48588	A2	19890628	HU 1987-3002	19870702
HU 204254	B	19911230		
CN 87104641	A	19880203	CN 1987-104641	19870703
US 4990521	A	19910205	US 1989-405575	19890908
PRIORITY APPLN. INFO.:			US 1986-882067	A 19860703
			US 1987-57451	B1 19870526
			EP 1987-201255	A 19870701
OTHER SOURCE(S):		MARPAT 109:6425		
GI				



AB The title compds. I [Ar = thienyl, furanyl, (un)substituted Ph, etc.; Ar¹, Ar² = Ph, halophenyl; R¹ = H, alkyl, arylalkyl, alkanoyl, (un)substituted aminoalkyl; R² = H, alkyl; R⁶, R⁷ = R², CH₂CH:CH₂, PhCH₂; NR⁶R⁷ = pyrrolidinyl, piperidinyl, morpholinyl, etc.; Z = CH₂CH₂, CH₂CMe] were prepared trans-4-[(Phenylmethyl)amino]-3-piperidinol was refluxed with K₂CO₃ in Me₂CHCH₂COMe and the product refluxed 24 h with furanylidene-methanaminium bromide II to give piperidinebutanamide III (R = PhCH₂). The latter was hydrogenolized to III (R = H) which was stirred overnight with 3-(F₃C)C₆H₄COCl in CH₂Cl₂ containing Et₃N to give III [R = 3-(F₃C)C₆H₄CO] which had an ED₅₀ of 0.15 mg/kg orally against ricinus

oil-induced diarrhea in rats with an oral ED50 of >160 mg/kg in the tail withdrawal test.

L3 ANSWER 41 OF 45 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1988:485653 HCAPLUS

DOCUMENT NUMBER: 109:85653

TITLE: Excretion and biotransformation of cisapride in rats after oral administration

AUTHOR(S): Meuldermans, Willem; Hendrickx, Jan; Lauwers, William; Hurkmans, Robert; Mostmans, Erik; Swysen, Eric; Bracke, Johan; Knaeps, Alfons; Heykants, Joseph
CORPORATE SOURCE: Dep. Drug Metab. and Pharmacokinet., Janssen Pharm., Beerse, B-2340, Belg.

SOURCE: Drug Metabolism and Disposition (1988), 16(3), 410-19
CODEN: DMDSAI; ISSN: 0090-9556

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The excretion and biotransformation of cisapride, a novel gastrokinetic drug, were studied after single (10, 40, and 160 mg/kg) and repeated (10 mg/kg/day) oral administration to rats, using 3 different radiolabels. In fasted rats, cisapride was absorbed almost completely, except for the 160 mg/kg dose. Cisapride was metabolized extensively to at least 30 metabolites. The excretion of the metabolites amounted to >80% of the dose at 24 h and was almost complete at 96 h after dosing. In bile duct-cannulated rats, 60% was excreted in the bile within 24 h, 45% of which underwent enterohepatic circulation. The main urinary metabolites, 4-fluorophenyl sulfate and norcisapride, primarily resulted from the N-dealkylation at the piperidine. Another major metabolic pathway was aromatic hydroxylation, occurring on either the 4-fluorophenoxy or the benzamide rings. The resulting phenolic metabolites were eliminated as conjugates in the bile; a large portion of them were subjected to a rapid enterohepatic circulation before their final excretion in the feces. Minor metabolic pathways included piperidine oxidation, O-dealkylation, O-demethylation of the methoxy substituent at the benzamide, and amine glucuronidation. Only minor quant. dose- and sex-dependent differences could be observed for the mass balance of the metabolites. Upon repeated oral dosing, steady state excretion rates were already attained after 2-3 doses, and excretion and metabolite patterns were very similar to those after single dose administration.

L3 ANSWER 42 OF 45 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1988:485652 HCAPLUS

DOCUMENT NUMBER: 109:85652

TITLE: Excretion and biotransformation of cisapride in dogs and humans after oral administration

AUTHOR(S): Meuldermans, Willem; Van Peer, Achiel; Hendrickx, Jan; Lauwers, William; Swysen, Eric; Bockx, Marc; Woestenborghs, Robert; Heykants, Joseph
CORPORATE SOURCE: Dep. Drug Metab. and Pharmacokinet., Janssen Pharm., Beerse, B-2340, Belg.

SOURCE: Drug Metabolism and Disposition (1988), 16(3), 403-9
CODEN: DMDSAI; ISSN: 0090-9556


DOCUMENT TYPE: Journal

LANGUAGE: English

AB The excretion and biotransformation of cisapride, a novel gastrokinetic drug, were studied after a single oral dose of [¹⁴C]cisapride in dogs and humans. The excretion of radioactivity amounted to 97% within 4 days after a 1 mg/kg dose in dogs (72% in feces and 25% in urine). After a 10-mg dose in humans, 44% was excreted in the 0-24-h urine and 37% in the 0-35-h feces; excretion was complete within 4 days. Excretion of the parent drug was greater in dogs (0.4-1.3% of the dose in urine, 23% in feces) than in humans (0.2% in urine, 4-6% in feces). This was due, at least in part, to a larger proportion of amine glucuronidation and sulfation in dogs. N-Dealkylation at the piperidine N resulting in the


main urinary metabolite, norcisapride, and aromatic hydroxylation of the 4-fluorophenyl ring were major metabolic pathways in both species. Norcisapride excretion accounted for 14% of the dose in dogs and 41-45% in humans. Minor metabolic pathways were O-dealkylation at the 4-fluorophenoxy group and piperidine oxidation. Peak plasma levels and area under the concentration-time curve values of norcisapride in humans were 8-9 times lower than those of cisapride. Apart from more amine conjugation in dogs, the biotransformation of cisapride was similar in dogs and humans.

L3 ANSWER 43 OF 45 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1988:510216 HCAPLUS
 DOCUMENT NUMBER: 109:110216
 TITLE: Synthesis of 3H- and 14C-cisapride
 AUTHOR(S): Janssen, C. G. M.; Lenoir, H. A. C.; Thijssen, J. B. A.; Knaeps, A. G.; Heykants, J. J. P.
 CORPORATE SOURCE: Dep. Drug Metab. Pharmacokinet., Janssen Pharm., Beerse, B-2340, Belg.
 SOURCE: Journal of Labelled Compounds and Radiopharmaceuticals (1987), 24(12), 1493-501
 CODEN: JLCRD4; ISSN: 0362-4803
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 109:110216
 GI



AB Title compds. I (X = C, R = H, R1 = T; R = T, R1 = H) and I (X = 14C, R = R1 = H) were prepared

L3 ANSWER 44 OF 45 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1986:583409 HCAPLUS
 DOCUMENT NUMBER: 105:183409
 TITLE: Synthesis of cisapride, a gastrointestinal stimulant derived from cis-4-amino-3-methoxypiperidine
 AUTHOR(S): Van Daele, Georges H. P.; De Bruyn, Marcel F. L.; Sommen, Francois M.; Janssen, Marcel; Van Nueten, Jan M.; Schuurkes, Jan A. J.; Niemegeers, Carlos J. E.; Leysen, Josee E.
 CORPORATE SOURCE: Dep. Chem. Res., Janssen Pharm. Res. Lab., Beerse, B-2340, Belg.
 SOURCE: Drug Development Research (1986), 8(1-4), 225-32
 CODEN: DDREDK; ISSN: 0272-4391
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 105:183409
 GI



AB A series of cis- and trans-4-amino-3-methoxypiperidinebenzamides (I; R1 = PhCH2, 4-FC6H4O(Me)2, MeO(CH2)3, Et, etc.) were prepared and tested for dopamine antagonist as well as gastric contraction stimulatory activities in exptl. animals. Several of the prepared compds. stimulated gastric motility without having dopamine antagonist activity. Structure-activity relationship is discussed.

L3 ANSWER 45 OF 45 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1983:594812 HCAPLUS
DOCUMENT NUMBER: 99:194812
TITLE: N-(3-Hydroxy-4-piperidinyl)benzamide derivatives
INVENTOR(S): Van Daele, Georges
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: Eur. Pat. Appl., 137 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 76530	A2	19830413	EP 1982-201080	19820903
EP 76530	A3	19830803		
EP 76530	B1	19851211		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
CA 1183847	A1	19850312	CA 1982-409480	19820816
AT 16928	E	19851215	AT 1982-201080	19820903
SU 1593569	A3	19900915	SU 1982-3489954	19820910
RO 84704	P	19840717	RO 1982-108663	19820921
CZ 280009	B6	19950913	CZ 1982-6821	19820923
SK 278380	B6	19970205	SK 1982-6821	19820923
DD 203048	A5	19831012	DD 1982-243524	19820927
DK 8204351	A	19830402	DK 1982-4351	19820930
DK 165365	B	19921116		
DK 165365	C	19930405		
FI 8203348	A	19830402	FI 1982-3348	19820930
FI 78073	B	19890228		
FI 78073	C	19890612		
NO 8203297	A	19830405	NO 1982-3297	19820930
NO 159378	B	19880912		
NO 159378	C	19881221		
AU 8288925	A1	19830414	AU 1982-88925	19820930
AU 553845	B2	19860731		
HU 27373	O	19831028	HU 1982-3147	19820930
HU 189629	B	19860728		
ES 516131	A1	19831101	ES 1982-516131	19820930
ZA 8207194	A	19840530	ZA 1982-7194	19820930
IL 66916	A1	19850929	IL 1982-66916	19820930
JP 58090552	A2	19830530	JP 1982-171112	19821001
JP 02045625	B4	19901011		
PL 138053	B1	19860830	PL 1982-238469	19821001
PL 138475	B1	19860930	PL 1982-245223	19821001
ES 542439	A3	19851216	ES 1985-542439	19850422
US 4962115	A	19901009	US 1989-443060	19891128
US 5057525	A	19911015	US 1990-535939	19900611
US 5137896	A	19920811	US 1991-748227	19910820
PRIORITY APPLN. INFO.:				A 19811001
				A 19820730
				A 19820903
				B1 19840718
				B1 19881017


US 1989-443060

A3 19891128

US 1990-535939

A3 19900611

GI



AB Piperidinybenzamides I [R = alkoxycarbonyl, (un)substituted alkyl, cycloalkyl, aralkyl, etc.; R1 = H, alkyl, aralkyl, aminoalkyl, alkylcarbonyl; R2 = H, alkyl; R3 = (un)substituted Ph] (244 compds.) were prepared Thus, cis-I [R = R2 = H, R1 = Me, R3 = 5,4,2-Cl(H2N)(MeO)C6H2] was treated with 4-FC6H4O(CH2)3Cl to give 42.8% cis-I [R = 4-FC6H4O(CH2)3, R1 = Me, R2 = H, R3 = 5,4,2-Cl(H2N)(MeO)C6H2] (II). II had a min. effective concentration of 0.00016 mg/L for stimulation of contraction of isolated guinea pig ileum.

=> d ibib abs 1

L3 ANSWER 1 OF 45 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:272735 HCAPLUS

DOCUMENT NUMBER: 144:305166

TITLE: Selective serotonin reuptake inhibitors used in combination with 5-HT4 receptor agonists, pharmaceutical compositions, and therapeutic uses

INVENTOR(S): Debonnel, Guy; Lucas, Guillaume

PATENT ASSIGNEE(S): McGill University, Can.

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006029520	A1	20060323	WO 2005-CA1401	20050914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2004-609275P P 20040914

AB The invention discloses a combination of a serotonin selective reuptake inhibitor (SSRI) and an agonist of the serotonin 4 (5-HT4) receptor to augment and/or provide faster onset of the therapeutic effect of the SSRI alone or administered with any other compound which causes an elevation in the level of extracellular serotonin (5-HT). The invention also discloses a pharmaceutical formulation comprising the combination, as well as a

method and use of the combination in the treatment of depression, anxiety, obsessive compulsive disorder (OCD) or other disease or disorder responsive to a SSRI.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s serotonin reuptake inhibitor?
L4 16050 SEROTONIN REUPTAKE INHIBITOR?

=> s prokinetics or motility
L5 160065 PROKINETICS OR MOTILITY

=> s l4 and l5
L6 389 L4 AND L5

=> s l4 (S) l5
L7 48 L4 (S) L5

=> dup rem l7
PROCESSING COMPLETED FOR L7
L8 45 DUP REM L7 (3 DUPLICATES REMOVED)

=> d ibib abs 41-45

L8 ANSWER 41 OF 45 USPATFULL on STN
ACCESSION NUMBER: 1998:42357 USPATFULL
TITLE: Compounds having effects on serotonin-related systems
INVENTOR(S): Hibschan, David J., Bangersville, IN, United States
Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5741789		19980421
APPLICATION INFO.:	US 1995-467434		19950606 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Kifle, Bruck		
LEGAL REPRESENTATIVE:	Palmberg, Arleen, Boone, David E.		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	5902		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 42 OF 45 USPATFULL on STN
ACCESSION NUMBER: 97:38539 USPATFULL

TITLE: Compounds having effects on serotonin-related systems
 INVENTOR(S): Audia, James E., Indianapolis, IN, United States
 Hibschan, David J., Bargersville, IN, United States
 Krushinski, Jr., Joseph H., Indianapolis, IN, United States
 Mabry, Thomas E., Indianapolis, IN, United States
 Nissen, Jeffrey S., Fishers, IN, United States
 Rasmussen, Kurt, Fishers, IN, United States
 Rocco, Vincent P., Indianapolis, IN, United States
 Schaus, John M., Zionsville, IN, United States
 Thompson, Dennis C., Indianapolis, IN, United States
 Wong, David T., Indianapolis, IN, United States
 PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5627196		19970506
APPLICATION INFO.:	US 1995-468948		19950606 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Bottino, Anthony		
LEGAL REPRESENTATIVE:	Jones, Joseph A., Boone, David E.		
NUMBER OF CLAIMS:	56		
EXEMPLARY CLAIM:	1		
LINE COUNT:	5947		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 43 OF 45 USPATFULL on STN

ACCESSION NUMBER: 97:25037 USPATFULL
 TITLE: Compounds having effects on serotonin-related systems
 INVENTOR(S): Audia, James E., Indianapolis, IN, United States
 Krushinski, Jr., Joseph H., Indianapolis, IN, United States
 Rasmussen, Kurt, Fishers, IN, United States
 Rocco, Vincent P., Indianapolis, IN, United States
 Schaus, John M., Zionsville, IN, United States
 Thompson, Dennis C., Indianapolis, IN, United States
 Wong, David T., Indianapolis, IN, United States
 PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5614523		19970325
APPLICATION INFO.:	US 1995-470512		19950606 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Bottino, Anthony		
LEGAL REPRESENTATIVE:	Jones, Joseph A., Boone, David E.		

NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 5755

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 44 OF 45 USPATFULL on STN

ACCESSION NUMBER: 96:106493 USPATFULL

TITLE: Compounds having effects on serotonin-related systems

INVENTOR(S): Krushinski, Jr., Joseph H., Indianapolis, IN, United States

Rasmussen, Kurt, Fishers, IN, United States

Rocco, Vincent P., Indianapolis, IN, United States

Schaus, John M., Zionsville, IN, United States

Thompson, Dennis C., Indianapolis, IN, United States

PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5576321		19961119
APPLICATION INFO.:	US 1995-468900		19950606 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Bottino, Anthony		
LEGAL REPRESENTATIVE:	Jones, Joseph A., Boone, David E.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
LINE COUNT:	5725		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 45 OF 45 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN

ACCESSION NUMBER: 1987-073959 [11] WPIDS

DOC. NO. CPI: C1987-030780

TITLE: New substd. hexa hydro-aryl quinolizine cpds. - with selective alpha-2 adrenergic receptor antagonist activity, useful as antidepressants, antihypertensives, etc..

DERWENT CLASS: B02

INVENTOR(S): BALDWIN, J J; GUARE, J P; HUFF, J R; SAKURAI, Y; VACCA, J P

PATENT ASSIGNEE(S): (MERI) MERCK & CO INC

COUNTRY COUNT: 9

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
-----------	------	------	------	----	----

```

-----
EP 214556      A  19870318 (198711)* EN   46
   R: CH DE FR GB IT LI NL
JP 62111986    A  19870522 (198726)
US 4686226     A  19870811 (198734)      13
EP 214556      B  19901122 (199047)
   R: CH DE FR GB IT LI NL
DE 3675714     G  19910103 (199102)

```

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 214556	A	EP 1986-111890	19860828
JP 62111986	A	JP 1986-206066	19860903
US 4686226	A	US 1985-771927	19850903

PRIORITY APPLN. INFO: US 1985-771927 19850903

AN 1987-073959 [11] WPIDS

AB EP 214556 A UPAB: 19930922

Cpds. of formula (I) and slats are new where Ar is X,Y-benzo-, X,Y-benzo(b)furo-, X,Y-benzo(b)thieno-, pyridino-, thiazolo-, imidazo-, pyrazolo-, thieno- or furo-; X and Y are each H, halogen, OH, 1-3C alkoxy or 1-6C alkyl; R is COOR1, -CR1R4Z, -CR1 = Q or a gp. of formula (II); R1 is H or opt. branched 1-5C alkyl; R2 is H, 1-5C alkyl or 1-5C alkylidene; Q is O or =N-OR1; Q1 is COOR1, SO2R1 or SO2NR1'R2'; R1' and R2' are each R1 and R2 respectively, or together complete a 5- or 6-membered heterocycle opt. containing further heteroatoms; Z is OR3, SR3 or NR2R3; R3 is H, 1-5C alkyl (opt. substd.by OH, COOR1, SO2R2 or -NR2-SO2R2), COOR2, SO2R2 or SO2NR2R3; R4 is 1-5C alkyl or 1-5C alkylidene; and the broken lines are opt. double bonds.

USE/ADVANTAGE - (I) are selective alpha2-adrenoceptor antagonists, useful as e.g. antidepressants, antihypertensives, ocular antihypertensives, antidiabetic or antiobesity agents, as platelet aggregation inhibitors or modifiers of gastrointestinal motility. Doses are e.g. 0.01-20, pref. 0.1-10 mg/kg/day, opt. divided. For treating depression, (I) may be co-administered with other antidepressants, e.g. anitriptylene, imipramine or other norepinephrine or serotonin reuptake inhibitor or a monoamine oxidase inhibitor.

O/O

ABEQ EP 214556 B UPAB: 19930922

Cpds. of formula (I) and slats are new where Ar is X,Y-benzo-, X,Y-benzo(b)furo-, X,Y-benzo(b)thieno-, pyridino-, thiazolo-, imidazo-, pyrazolo-, thieno- or furo-; X and Y are each H, halogen, OH, 1-3C alkoxy or 1-6C alkyl; R is COOR1, -CR1R4Z, -CR1 = Q or a gp. of formula (II); R1 is H or opt. branched 1-5C alkyl; R2 is H, 1-5C alkyl or 1-5C alkylidene; Q is O or =N-OR1; Q1 is COOR1, SO2R1 or SO2NR1'R2'; R1' and R2' are each R1 and R2 respectively, or together complete a 5- or 6-membered heterocycle opt. contg. further heteroatoms; Z is OR3, SR3 or NR2R3; R3 is H, 1-5C alkyl (opt. substd.by OH, COOR1, SO2R2 or -NR2-SO2R2), COOR2, SO2R2 or SO2NR2R3; R4 is 1-5C alkyl or 1-5C alkylidene; and the broken lines are opt. double bonds.

USE/ADVANTAGE - (I) are selective alpha2-adrenoceptor antagonists, useful as e.g. antidepressants, antihypertensives, ocular antihypertensives, antidiabetic or antiobesity agents, as platelet aggregation inhibitors or modifiers of gastrointestinal motility. Doses are e.g. 0.01-20, pref. 0.1-10 mg/kg/day, opt. divided. For treating depression, (I) may be co-administered with other antidepressants, e.g. anitriptylene, imipramine or other norepinephrine or serotonin reuptake inhibitor or a monoamine oxidase inhibitor.

O/O

ABEQ US 4686226 A UPAB: 19930922

Substd. hexahydrobenzo (b) furo-and thieno-quinolizines and salts of formula (I) are new. In (I), Ar is X, Y-benzol (B)-furo-and -thieno-: X and Y are each H, halo, OH, 1-3C alkoxy, 1-6C alkyl; R is -COOR₁ where R₁ is H, 1-5C alkyl, R₂-C (=) COOR₁, with R₂ is H, 1-5C alkyl or alkylidene; R₂-C (=) SO₂R₁, R₂-C (=) SO₂NR₁R₂, where R₁ and R₂ may be joined to form pyrrolidine or piperidine, R₁C (-) = Q where Q is O or NOR₁, -CR₁R₄Z where Z is OR₃, SR₃, NR₂R₃; R₄ is 1-5C alkyl or -alkylidene.

(I) may be prepd. e.g. by Wittig reaction of 2-oxo-quino-lizine with KH or nBuLi etc. and opt. PdC/H₂ redn. to satd. analogues.

USE - (I) are selective alpha₂-adrenoreceptor antagonists used to block norepinephrine and/or serotonin neuronal reuptake in cns. and increase their availability as neurotransmitters. Used to treat depression, hypertension, diabetes, obesity, to inhibit platelet aggregation and modify G.I. motility. Dosage is e.g. 0.01 - 20 (0.1-10) mg/kg/day.

=> log h

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	61.61	72.80
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-5.25	-5.25

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:21:21 ON 21 JUL 2006